We describe glycoprotein (GP) Ib as a mediator of adhesion t o fibronectin, specifically in flow. A monoclonal antibody (MoAb) directed to the von Willebrand factor (vWF)-binding site on this receptor or the absence of this receptor on the platelet membrane, in the case of a patient with the BernardSoulier syndrome, reduced platelet coverage t o fibronectin t o approximately 30% of the control value. A MoAb directed to the GP Ib-binding site on vWF showed a similar effect. With washed platelets in the absence of plasma vWF, the inhibitory effect of the anti-GP Ib antibody was the same as with whole blood. No inhibition with the anti-GP Ib antibody was observed when we used blood from patients with severe von Willebrand disease (vWD) or from a patient with vWD type I (platelet low). Addition of vWF t o vWD blood LATELET adhesion to the subendothelium of an injured vessel wall is a complex process that requires the contributions of several adhesive proteins.' One of these proteins is fibronectin, which is present in plasma, the subendothelium, and the a-granules of platelets. Fibronectin supports platelet adhesion and spreading under and flow4 conditions. In addition, fibronectin promotes platelet adhesion in flow to other surfaces, such as nonfibrillar collagens type I and the extracellular matrix of cultured endothelial and the subendothelium of the vessel wall.' Platelet adhesion to purified fibronectin has been shown to depend on both glycoprotein (GP) IIb/IIIa and very late antigen (VLA)-5 under both static? and flow conditiom4 However, experiments in our laboratory in which we used fibronectin as a control surface to study the effect of an anti-GP Ib antibody on platelet adhesion to several adhesive proteins revealed that platelet adhesion to fibronectin in flow was also decreased by this antibody.
t o approximately 30% of the control value. A MoAb directed to the GP Ib-binding site on vWF showed a similar effect. With washed platelets in the absence of plasma vWF, the inhibitory effect of the anti-GP Ib antibody was the same as with whole blood. No inhibition with the anti-GP Ib antibody was observed when we used blood from patients with severe von Willebrand disease (vWD) or from a patient with vWD type I (platelet low). Addition of vWF t o vWD blood LATELET adhesion to the subendothelium of an injured vessel wall is a complex process that requires the contributions of several adhesive proteins.' One of these proteins is fibronectin, which is present in plasma, the subendothelium, and the a-granules of platelets. Fibronectin supports platelet adhesion and spreading under and flow4 conditions. In addition, fibronectin promotes platelet adhesion in flow to other surfaces, such as nonfibrillar collagens type I and the extracellular matrix of cultured endothelial and the subendothelium of the vessel wall.' Platelet adhesion to purified fibronectin has been shown to depend on both glycoprotein (GP) IIb/IIIa and very late antigen (VLA)-5 under both static? and flow conditiom4 However, experiments in our laboratory in which we used fibronectin as a control surface to study the effect of an anti-GP Ib antibody on platelet adhesion to several adhesive proteins revealed that platelet adhesion to fibronectin in flow was also decreased by this antibody.
In this report, we further explore this phenomenon. We describe an indirect mechanism of adhesion to fibronectin via GP Ib that only took place in the presence of von Willebrand factor (vWF), despite the fact that we could not demonstrate direct binding of vWF to fibronectin. Our observations are in agreement with other studies showing vWF dependence for adhesion to other adhesive proteins, such as fibrin"' and collagen.'."^'* However, these data are unique in that they suggest a role for vWF in platelet adhesion at a relatively low shear rate. We hypothesize about the mecha-resulted in restoration of adhesion. lmmunoelectron microscopy on platelets adhering t o fibronectin showed that GP Ib was homogeneously distributed over the entire surface of the platelet. vWF was present at the central zone and the edges of the platelet and at the basal interface between the platelet and the fibronectin surface. No direct binding of vWF t o fibronectin could be demonstrated. These data indicate that GP Ib-mediated adhesion t o fibronectin fully depends on vWF and that normal levels of plasma or platelet vWF are sufficient for optimal adhesion t o fibronectin. The data suggest that the presence of platelets during perfusion is a prerequisite for vWF t o support platelet adhesion t o fibronectin. 0 1995 by The American Society of Hematology.
nism(s) that may be responsible for GP Ib-vWF-mediated adhesion to fibronectin.
EXPERIMENTAL PROCEDURES

Purijication of Proteins
Purified human fibronectin was prepared as described previously by affinity chromatography from citrated plasma over a gelatinSepharose (Pharmacia, Uppsala, Sweden) column." The isolated protein was 99% homogeneous fibronectin, as judged by polyacrylamide electrophoresis, and no contaminating vWF or fibrinogen was demonstrated by enzyme-linked immunosorbent assay.
vWF was prepared from human cryoprecipitates using polyethyleneglycol precipitation and gel filtration on Biogel A-1Sm (Biorad, Richmond, CA), as described previo~sly.'~
Preparation of vWF-Depleted Plasma
Plasma depleted of vWF was obtained by affinity chromatography. Citrated plasma was passed over a column of CNBr-activated Sepharose (Pharmacia), to which a monoclonal antibody (MoAb) against vWF was coupled according to the manufacturer's instructions. The level of vWF was approximately 0.04 U h L , which is 4% of the normal plasma level of I U/mL.
Preparation of Protein-Coated Coverslips
Glass coverslips (for perfusion: 18 X 18 mm; for the static experiment: circular, diameter of 12 mm; Menzel, Braunschweig, Germany) were cleaned in 80% alcohol, rinsed in distilled water, dried thoroughly, and then sprayed with protein. Fibronectin, dialyzed against 0.05 mol& ammonium acetate pH 7.4, was sprayed at a concentration of S pglcm' with a retouching airbrush (Badger model 100: Badger Brush CO, Franklin Park, IL) in such a way that each layer of protein had been dried before the next layer of protein was sprayed. After spraying, the coverslips were incubated with a
1%
human albumin solution in phosphate-buffered saline (PBS; I O mmol/L phosphate buffer, pH 7.4, and 0.15 molL NaCI) for I hour to block aspecific adhesion to glass. No adhesion was found with coverslips coated with albumin alone. 
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Polyclonal Antibodies
Rabbit polyclonal anti-human vWF antibodies, used for immunogold labeling, were purchased from Dakopatts (Glostrup, Denmark). Rabbit polyclonal anti-GP Ib antibodies, also used for immunogold labeling, were prepared in our own laboratory. Platelets from a patient with the Bernard-Soulier syndrome (BS) showed no staining with these antibodies.
Perfusion Studies
Perfusion studies were performed in a parallel-plate perfusion chamber with well-defined rheologic characteristics designed to accommodate duplicate glass coverslips." Whole blood obtained by venipuncture from healthy volunteer donors or patients was anticoagulated with 1/10 volume 110 mmol/L trisodium citrate. Whole blood (15 mL) was prewarmed at 37°C for 5 minutes and then recirculated through the perfusion chamber, which contained two protein-sprayed glass coverslips, for 5 minutes at a shear rate of 300 S". After perfusion, the coverslips were removed and rinsed with 10 mmoVL HEPES buffer containing 150 mmoVL NaCl, pH 7.35. Then they were fixed in 0.5% glutaraldehyde in PBS, dehydrated in methanol, and stained with May-Griinwald-Giemsa as previously described.'8 Platelet adhesion was evaluated with a light microscope at 1,OOOX magnification, and the coverage was measured with an Image Analyzer (AMS 40-10; Saffron Walden, UK). Platelet coverage, expressed as the percentage of the surface covered with platelets, is the average of 60 fields per coverslip.
For experiments investigating the influence of platelet vWF, platelets were washed as previously described" and reconstituted in vWFdepleted plasma or in a 4% (wt/vol) human albumin solution (HAS) in Krebs-Ringer buffer (4 mmol/L KCI, 107 mmol/L NaCI, 20 mmoll L NaHCO,, and 2 mmoVL Na2S04, containing 19 mmol/L citrate, 2.5 rnmoVL CaCI,, and 5 mmol/L glucose; pH 7.35).
Static Adhesion Assay
The static adhesion assay with platelets from the patient with BS was performed on circular coverslips with a surface area of 1.1 cm2, which were placed in a 24-well plate (Costar, Cambridge, MA). Because both the patient and matched controls (see below) have giant platelets, red blood cells were allowed to settle for 2 hours to obtain platelet-rich plasma. To each well, 500 pL platelet suspension was added, and platelets were allowed to adhere for 1 hour at 37°C. Subsequently, coverslips were rinsed, stained, and evaluated as described above.
Patient Studies
One patient with BS, who has been described previously," was tested twice in perfusion and once in the static adhesion assay. Because this patient has a decreased platelet count with the presence of giant platelets, the following controls were included in each of the experiments: one individual with the May-Hegglin abnormality (MH) and one with an essential macrothrombocytopenia (MT).
These so called large-platelet controls also have platelets with a bigger size than normal individuals, and their platelet counts were comparable with the platelet count of the patient with BS. However, in contrast with the patient, no hemostatic defects have been observed in either one of the large-platelet controls. This was also reflected by the normal bleeding times of the large-platelet controls (Ivy bleeding time measurement; MHl, 4.25 minutes; MH2, 2.30 minutes; MT, 3.25 minutes) and the prolonged bleeding time of the patient with BS (Ivy; greater than 30 minutes). Flow-cytometric analysis showed that the patient with BS was negative for GP Ib, while the patient's GP IIb-IIIa level was normal. For the controls, no decrease in either receptor was detected.
To study the involvement of vWF in platelet adhesion to fibronectin, two patients with severe von Willebrand disease (vWD) were tested. One of them, whom we will refer to as patient 111-1, has been described previously.2' No vWF was present in their platelets or plasma (in plasma: <0.01 UlmL vWF antigen [vWF:Ag]). Furthermore, we investigated one patient with vWD type I (platelet low), herein referred to as patient I, with a low vWF level in the plasma (0.04 UlmL ristocetin cofactor activity and 0. I UlmL vWF:Ag) and no vWF in the platelets. With one patient with severe vWD (patient 111-2), we performed an experiment in which we added different recombinant forms of vWF to the vWD blood to study the effect on adhesion. These included full length vWF, the AA1 mutant (lacking the GP Ib-binding site), and the RGGS mutant (lacking the GP IIbAIIa-binding site), which have been previously described."
v WF Localization With Electron Microscopy
Whole-mount preparations and ultra-thin cryosections of perfused coverslips were prepared as described elsewhere.', Immunolabeling was performed with polyclonal anti-human vWF antibodies or anti-GP Ib antibodies, which were visualized using Protein-A gold markers prepared according to the method of Slot et aLZ4 Specificity of immunolabeling was verified using Protein-A gold alone, which did not show any labeling. Both whole-mount preparations and ultra-thin cryosections were examined in a JEOL 1200EX electron microscope (JEOL, Tokyo, Japan) at 100 kV. A 12" tilting angle was used to produce stereo-paired electron micrographs.
Statistical Analyses
Significance of difference between means of total surface coverage of two samples was calculated with a paired Student's r test. Comparison of two series of coverslips obtained within one experiment, as in the case of patient studies, was performed with an unpaired Student's t-test.zs
RESULTS
Perfusion Studies
Antibody studies.
Platelet adhesion to fibronectin was studied under conditions that we have previously shown to be optimal, that is, we used a 5-pg/cm2 concentration of fibronectin on the coverslip, and we perfused at a shear rate of 300 s".~ We first studied the effect of an anti-GP Ib antibody ( Table 1) . Added to whole blood, MoAb AK2 significantly reduced adhesion to fibronectin by 68%. This degree of inhibition was repetitively observed, although the absolute amount of surface coverage varied among experiments (between 12% and 35%), depending on the batch of fibronectin and the donor. The control antibody AK3 had no effect. Platelet spreading was not affected by MoAb AK2 (compare Fig 1A and B) . The inhibition by MoAb AK2 was specific for flow, because under static conditions, no inhibition was observed with this MoAb or with MoAb 6D1, For personal use only. on October 3, 2017. by guest www.bloodjournal.org From which is also directed to the vWF-binding site on GP Ib (data not shown). Because GP Ib has been described as a receptor for vWF, we were interested to see whether an antibody directed to the GP Ib-binding site on vWF exerted a similar effect on platelet adhesion to fibronectin under flow conditions. We found a 58% inhibition, and also in this case, 
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platelet spreading was not altered (compare Fig I A and C) . We also perfused fibronectin-sprayed coverslips with washed platelets reconstituted in either vWF-depleted plasma or a 4% HAS solution. In this way, we studied the effect of the anti-GP Ib antibody MoAb AK2 under conditions where only platelet vWF was present. Both in the presence (reconstitution in vWF-depleted plasma) and absence (reconstitution in HAS) of other plasma proteins, the antibody was inhibitory. The degree of inhibition, 53% and 64%.
respectively, was comparable with the inhibition found in the whole-blood perfusion. No effect was observed with MoAb AV!.
Patient Studies
Bernard-Soldier syndrome. To confirm the role of GP Ib, we performed two perfusion experiments with whole blood of a patient with BS ( Table 2 ). This patient was completely negative for GP lb. Because this patient had a decreased platelet count in combination with the presence of giant platelets, we included in each of our adhesion studies, besides a healthy control, one individual with the MH abnormality and one individual with an essential MT. Platelet counts for the patient with BS and the large platelet controls were comparable, whereas the healthy control had a higher platelet count (experiment 1: BS, 24,0OO/pL; large platelet controls, 30,00O/pL and 42,OOO/pL, healthy control, 200,00O/p,L; experiment 2: BS, 35,0OO/pL. large platelet controls, 48,00O/pL and 56,0OO/pL; healthy control, 215,0OO/pL). Both experiments show that with the large platelet controls, adhesion was already significantly reduced by 40% to 66% compared with the healthy control. However, the surface coverage with the patient with BS was further reduced to 49% or 28% (experiment 1) or 33% (experiment 2) of the coverage found with the large platelet controls 
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on the same day. In all cases, platelet spreading was not impaired.
On one occasion we also performed a static experiment. Because the giant platelets were too large to prepare plateletrich plasma by centrifugation, we allowed the red blood cells to settle for 2 hours. In this way, we obtained platelet-rich plasma with the following platelet counts: BS, 19,00O/pL; large platelet controls, 30,OOO/pL and 35,OOO/pL. Plateletrich plasma for the healthy control was prepared in the usual way and adjusted to 30,OOO/pL by addition of platelet-poor plasma. Platelets of the healthy control, at this low platelet count, did not adhere to fibronectin. Platelets of the patient with BS and the large platelet controls did adhere to fibronectin. However, in contrast with the perfusion studies, there was no difference in percentage surface coverage between them: they all showed approximately 10% surface coverage.
vWD. The antibody studies showed both GP Ib and vWF to be important for adhesion to fibronectin in flow. To investigate whether GP Ib is also involved in adhesion to fibronectin in the absence of vWF, we performed perfusions with blood from three different patients with vWD (Table 3) . We found that the inhibitory effect of the anti-GP Ib antibody AK2 was lost for the two patients with severe vWD (patient 111-1 and 111-2), as well as the patient with vWD type I (platelet low; patient I). Control donors on the respective days showed inhibition of adhesion by this antibody of 75%, 66%, and 45% (not shown), indicating that the antibody was working well. Addition of purified plasma vWF to vWD blood at a final concentration of 1 U/mL resulted in an increase of surface coverage of 121 % (patient 111-2) and 153% (patient I).
Whole blood from patient 111-2 was further used to test the effect of addition of different recombinant proteins of vWF on adhesion (Table 4) . Addition of mutant RGGS, which does not contain the recognition sequence for GP IIb/ IIIa but has an intact GP Ib-binding site, restored adhesion to the same level as full-length vWF. In contrast, mutant AA1 which contains the RGD site but lacks an intact GP Ib-binding site, showed no increase of adhesion compared with the coverage found when medium (vehicle solution) was added to the perfusate.
The experiments with the patients with vWD clearly Fibronectin-sprayed coverslips were perfused for 5 minutes with whole blood from a patient with severe vWD (patient 111-2 in Table 3 showed that GP Ib-mediated adhesion to fibronectin totally depended on the presence of vWF, suggesting that vWF forms a bridge between fibronectin on the coverslip and GP Ib on the platelet. However, when we incubated sprayed fibronectin for 1 hour with a solution of 1 U/mL purified and radiolabeled plasma vWF, we were not able to demonstrate direct binding of vWF to fibronectin (result not shown). In addition, electron microscopic whole-mount examination of fibronectin-sprayed coverslips that were perfused for 5 minutes at a shear rate of 300 S" with normal plasma, to which red blood cells but no platelets were added, also showed no binding of vWF to fibronectin (a polyclonal anti-vWF antibody and protein-A gold were used to visualize the vWF; result not shown).
Localization Studies
Whole-mount evaluation. Figure 2A shows a representative example of a platelet adhering to fibronectin after a 5-minute perfusion with whole blood. The platelet has fully spread and has become activated, which is evident from the centralization of the a-granules in the center of the granulomere. Staining for vWF using a polyclonal antibody revealed the presence of two forms of vWF, a tangled form and an extended form, which have been described earlier. 26 On top of the platelet, the tangled form could be detected, mostly at the site of the granulomere. In addition, some vWF clusters were found at the site of the hyalomere. The extended form was found at the rims of the platelet; strings of vWF surrounded the platelet (Fig 2A, arrowheads) , almost like anchors, and stereomicrographs (Fig 2B) show that vWF molecules located at these sites stretched downward from the edge of the platelet (arrow) toward the fibronectin surface (double arrowhead), suggesting crosslinking between vWF and the fibronectin surface. Stereomicrographs (Fig 2C) also demonstrate that vWF could be detected at the abluminal site of the platelet (arrow). The same micrographs further show strands of vWF stretching from one platelet to another (double arrowhead). Up to now, we described the different sites on the platelet where vWF was detected. The next question to address was whether GP Ib was present at the same sites so that it could serve as receptor for this vWF. Figure 2D shows that after a 5-minute perfusion with whole blood, GP Ib was evenly distributed over the spread platelet.
Ultra-thin sectioning.
The reconstitution experiments and the perfusions with the patients with vWD showed that both platelet and plasma vWF can contribute to adhesion. Figure 3 shows micrographs obtained from coverslips that were perfused with washed platelets reconstituted in 4% HAS. Figure 3A shows a thin section of a platelet, fully spread on fibronectin, with vWF present in the open canalicular system (OCS; star) and secreted by the platelet (arrow). Figure 3B shows that, subsequently, the vWF could be found at the rims of the platelet (double arrowheads), apparently making contact with the fibronectin surface, just as with the whole-blood perfusion. The double arrowhead on the right points to a cluster at the basal interface of the platelet. The double arrowhead on the left seems to point to a separate vWF cluster. However, because this is a cryosection at a single level, it is conceivable that this cluster made contact with the adjacent platelet. We also perfused with severe vWD blood to which purified plasma vWF was added. Simi- lar to the perfusion with washed platelets reconstituted in 4% HAS, we found vWF to be localized at the basal interface, where the platelet made contact with the fibronectin surface (not shown).
DISCUSSION
Previous studies in our laboratory showed that platelet adhesion to fibronectin in flow is mediated by at least two receptors, GP IIblIIIa and VLA-5.4 However, experiments in our laboratory investigating the effect of an anti-GP Ib antibody on adhesion to different adhesive surfaces demonstrated that adhesion to fibronectin was decreased by this antibody. This result prompted us to examine the role of GP Ib in adhesion to fibronectin more closely.
In this report, we describe GP Ib as mediator of adhesion to fibronectin, specifically in flow. This was shown both in the antibody study and by the experiments with the patient with BS. In both cases, the surface coverage was approximately 30% of the control value. We also showed that the inhibitory effect of the anti-GP Ib antibody was lost when we used blood from patients with vWD in the perfusions, indicating that GP Ib does not bind directly to fibronectin, but requires vWF as an intermediate. With respect to the origin of the vWF contributing to adhesion, we found that both platelet and exogenously added vWF could participate in adhesion. The inhibition with the anti-GP Ib antibody in the reconstitution experiments (53% inhibition for reconstitution in vWF-depleted plasma, 6 4 % inhibition for reconstitution in HAS) was comparable with the inhibition found in whole-blood perfusions (68% inhibition). This suggests that platelet vWF on its own is sufficient to maintain the GP Ib-mediated adhesion to fibronectin and that other plasma proteins are not needed in this process. Addition of exogenous vWF to vWD blood also resulted in restoration of adhesion. These data indicate that normal levels of vWF in plasma or platelets are sufficient for optimal adhesion to fibronectin.
The electron microscopic studies showed that vWF could be detected at different locations: on top of the platelet, at the basal interface between the platelet and the fibronectin surface, and, most suggestive, at the edges of the platelet, where vWF molecules seem to serve as anchors.
The data summarized above are in direct contrast with our observation that vWF could not directly bind to fibronectin. We established this both under static conditions in the absence of other proteins and in flow in the presence of plasma proteins and red blood cells. These opposite results can be reconciled if we assume that the presence of adherent platelets is a prerequisite for vWF to promote adhesion to fibronectin. We can only speculate about the mechanism(s) that may be implicated in GP Ib-vWF-mediated adhesion to fibronectin. Platelets attached to fibronectin via the activation-independent receptor VLA-5"' and activated as a consequence of this initial contact may provide an unknown factor (factor 'X') that is able to crosslink vWF and fibronectin to each other (Fig 4, model I) . Once secreted by platelets, it may bind to the fibronectin surface, thereby serving as attachment sites for endogenous or plasma vWF. In turn, this immobilized vWF could then contribute to adhesion by binding to the GP Ib receptor."." Another option is that initial contact between the platelet and the fibronectin surface via VLAJ causes a conformational change in GP Ib, which enables the receptor to bind fluid-phase v W F even at this low shear rate. For GP IlblIIIa, such an activation on platelet adherence has already been de~cribed.'~ Once bound to GP Ib, vWF may be crosslinked to the fibronectin surface via factor 'X'. Whole-mount examination of coverslips perfused with whole blood (Fig 2A) showed no staining for vWF in areas where platelets had not adhered (about 80% of the total surface). This suggests that if there is a factor 'X', it only exerts its function on a local scale. We showed that after perfusion, GP Ib was equally distributed over the platelet surface, including the sites where we had observed vWF, indicating that GP Ib may serve as receptor for vWF at these sites. Apparently, GP IIbLIIa is not important for the binding 3459 of exogenous vWF, because addition to vWD blood of the AA1 mutant, which can be recognized by GP IIb/IIIa but not by GP Ib, did not result in an increased surface coverage. With respect to this point, we have no information on endogenous vWF.
Another explanation as to how GP Ib-vWF-mediated adhesion to fibronectin may occur is shown in Fig 4, model 11. In this model, vWF bound to its receptors on the adherent platelet may now (because it is immobilized) bind to GP Ib receptors on circulating platelets, thereby slowing them down and directing them towards the surface, which may accelerate the attachment of these newly arriving platelets.
In Fig 2C, such a crosslinking between platelets is shown.
This model explains the importance of GP Ib (compared with GP IIbLIIa) for the vWF-mediated adhesion, because we do not expect platelet-bound vWF to bind to nonactivated GP IIb/IIIa receptors on circulating platelet^.'^ At present, the models discussed above are hypothetical, and more research will be needed to clarify the exact mechanism(s) regulating vWF-dependent adhesion to fibronectin. However, fibronectin is not the only adhesive protein that shows vWF-dependent adhesion. This phenomenon has also been described for other adhesive proteins. Depending on the nature of the adhesive surface, vWF dependence occurs at different shear rates. For (non) fibrillar collagen types Is and III?." vWF-dependent adhesion was observed at shear rates above 800 and 650 S-', respectively; whereas for fibrin vWF-dependent, adhesion was established at a shear rate of 1,300 S-'.'' Binding sites for collagen have been clearly defined on vWF." For fibrin, as for fibronectin, no such sites have yet been specified. Studies on platelet adhesion to the subendothelium using vWD blood or blood from patients with BS emphasize the role of vWF at shear rates higher than 800 s-1.31-33 An antibody directed to the vWF-binding site on GP Ib inhibited adhesion to the subendothelium at shear rates of 500 S-' and higher.33 However, another study on adhesion to the subendothelium showed that, under specific experimental conditions, vWF was also important at a low shear rate of 200 s-1.34
In our study, we present clear evidence that platelet adhesion to fibronectin partially depends on the GP Ib-vWF interaction. Because this is not an isolated phenomenon, we may postulate that vWF plays a more important role in platelet adhesion at different shear rates than previously reported.
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